SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
SRX Global commented on industry activity in engineered T-cell therapies following Pfizer's $330 million upfront deal with Starna Therapeutics for pre-IND CAR-T programs. SRX is proceeding with its pending acquisition of CERo Therapeutics, which is advancing CER-1236, a clinical-stage engineered T-cell therapy currently in Phase 1/1b CERTAIN-T trials with seven patients dosed and no dose-limiting toxicities reported.